Multivariate Cox proportional hazards models for OS and PFS
| Pretreatment characteristic . | Hazard ratio . | 95% CI . | P . |
|---|---|---|---|
| PFS (n = 278) | |||
| Serum creatinine, mg/L | 1.5 | 1.1-2.0 | .0034 |
| Ln(platelets, ×109/L) | 0.62 | 0.49-0.80 | < .001 |
| Ln(LDH, IU/L) | 1.7 | 1.2-2.5 | .0040 |
| Ln(albumin, g/dL) | 0.14 | 0.044-0.42 | < .001 |
| No. of prior treatments | 1.12 | 1.02-1.23 | .017 |
| Fludarabine refractory vs others | 1.9 | 1.3-2.8 | < .001 |
| PFS (with cytogenetic analysis, n = 177) | |||
| Serum creatinine, mg/L | 2.0 | 1.2-3.2 | .0074 |
| Ln(platelets, ×109/L) | 0.66 | 0.49-0.88 | .0043 |
| Abnormality of chromosome 17 | 4.6 | 2.5-8.2 | < .001 |
| Complex karyotype, not chromosome 17* | 2.6 | 1.5-4.4 | < .001 |
| 11q deletion | 3.0 | 1.6-5.7 | < .001 |
| No. of prior treatments | 1.12 | 1.009-1.25 | .033 |
| Fludarabine refractory vs others | 2.3 | 1.5-3.5 | < .001 |
| OS (with cytogenetic analysis, n = 182) | |||
| Age, y | 1.03 | 1.005-1.05 | .019 |
| Serum creatinine, mg/L | 2.3 | 1.4-3.8 | .0020 |
| Ln(platelets, ×109/L) | 0.59 | 0.44-0.80 | < .001 |
| Abnormality of chromosome 17 | 5.2 | 2.8-9.6 | < .001 |
| Complex karyotype, not chromosome 17* | 1.9 | 1.1-3.2 | .015 |
| Prior treatments (> 3 vs 3 or less) | 1.7 | 1.008-2.6 | .047 |
| Fludarabine refractory vs others | 1.8 | 1.16-2.7 | .0082 |
| Pretreatment characteristic . | Hazard ratio . | 95% CI . | P . |
|---|---|---|---|
| PFS (n = 278) | |||
| Serum creatinine, mg/L | 1.5 | 1.1-2.0 | .0034 |
| Ln(platelets, ×109/L) | 0.62 | 0.49-0.80 | < .001 |
| Ln(LDH, IU/L) | 1.7 | 1.2-2.5 | .0040 |
| Ln(albumin, g/dL) | 0.14 | 0.044-0.42 | < .001 |
| No. of prior treatments | 1.12 | 1.02-1.23 | .017 |
| Fludarabine refractory vs others | 1.9 | 1.3-2.8 | < .001 |
| PFS (with cytogenetic analysis, n = 177) | |||
| Serum creatinine, mg/L | 2.0 | 1.2-3.2 | .0074 |
| Ln(platelets, ×109/L) | 0.66 | 0.49-0.88 | .0043 |
| Abnormality of chromosome 17 | 4.6 | 2.5-8.2 | < .001 |
| Complex karyotype, not chromosome 17* | 2.6 | 1.5-4.4 | < .001 |
| 11q deletion | 3.0 | 1.6-5.7 | < .001 |
| No. of prior treatments | 1.12 | 1.009-1.25 | .033 |
| Fludarabine refractory vs others | 2.3 | 1.5-3.5 | < .001 |
| OS (with cytogenetic analysis, n = 182) | |||
| Age, y | 1.03 | 1.005-1.05 | .019 |
| Serum creatinine, mg/L | 2.3 | 1.4-3.8 | .0020 |
| Ln(platelets, ×109/L) | 0.59 | 0.44-0.80 | < .001 |
| Abnormality of chromosome 17 | 5.2 | 2.8-9.6 | < .001 |
| Complex karyotype, not chromosome 17* | 1.9 | 1.1-3.2 | .015 |
| Prior treatments (> 3 vs 3 or less) | 1.7 | 1.008-2.6 | .047 |
| Fludarabine refractory vs others | 1.8 | 1.16-2.7 | .0082 |
CI indicates confidence intervals; Ln, natural logarithm; LDH, lactate dehydrogenase; PFS, progression-free survival; and OS, overall survival.
Complex karyotype excluding abnormalities of chromosome 17.